media – Page 117 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Gan & Lee Pharmaceuticals successfully achieved localization of insulin core components

According to the news, on April 23, Gan & Lee Pharmaceuticals announced that the localization project of the company’s core component of insulin products, the bromobutyl rubber piston of the cartridge bottle, has successfully passed the review of the National Center for Drug Evaluation (CDE) and activated the conversion to A, and can be officially used for the packaging and production of insulin products. This move marks that China’s insulin industry chain has achieved independent control in the field of key materials. As the first insulin company in China to realize the localization of this key material, Gan & Lee Pharmaceuticals has injected strong momentum into improving the safety of the drug supply chain and optimizing production costs.
- Source: drugdu
- 156
- April 25, 2025
Kelun Biotech launches another ADC drug clinical trial in the United States

Sichuan Kelun Biotech recently announced that it has obtained approval from the U.S. FDA for its new drug clinical trial (IND) application to initiate clinical research on SKB518, a potential first-in-class ADC drug. According to a press release from Kelun Biotech, SKB518 is an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7) developed using Kelun Biotech’s OptiDCTM platform technology based on the biological characteristics of the target. It has shown good efficacy and safety window in preclinical trials and is intended to be used to treat advanced solid tumors. Previously, in June 2024, the drug had obtained IND approval from NMPA for advanced solid tumors. The clinical approval in both China and the United States indicates that the global synchronous development strategy of SKB518 is progressing steadily. Protein tyrosine kinase 7 (PTK7) is a Wnt coreceptor that is expressed at low levels in normal epithelial, endothelial, and hematopoietic tissues, ...
- Source: drugdu
- 204
- April 25, 2025
Changchun High-Tech’s net profit was nearly halved last year. The performance of the three core businesses, including growth hormone, influenza vaccine, and varicella vaccine, all declined.

On April 20, Changchun High-Tech (000661.SZ) simultaneously released its 2024 annual report and 2025 first quarter report. In 2024, the company achieved operating income of 13.466 billion yuan, a year-on-year decrease of 7.55%; and achieved a net profit attributable to the parent of 2.583 billion yuan, a year-on-year decrease of 43.01%. In terms of a single quarter, in the fourth quarter of last year, Changchun High-Tech suffered a loss, with operating income of 3.08 billion yuan, a year-on-year decrease of 20.8%; net profit attributable to the parent company was a loss of 206 million yuan, a year-on-year decrease of 122.4%; in the first quarter of this year, although it remained profitable, it continued the “double decline” of last year, with a single-quarter income of 2.997 billion yuan, a year-on-year decrease of 5.66%; net profit attributable to the parent company was 473 million yuan, a year-on-year decrease of 44.95%. Changchun High-Tech ...
- Source: drugdu
- 285
- April 24, 2025
Vitamin B6 injection of China Resources Double Crane subsidiary passed the consistency evaluation

On April 22, China Resources Double Crane(600062) announced that its wholly-owned subsidiary China Resources Double Crane Limin Pharmaceutical (Jinan) Co., Ltd. recently received a VitaminB6 Injection “Notice of Approval of Drug Supplementary Application”. The drug has passed the generic drug quality and efficacy consistency evaluation, and has added a supplementary application for the 1ml:100mg specification. The approval of this consistency evaluation will be beneficial to the company’s market sales and competitiveness. As of the announcement date, Shuanghe Limin has invested 3.89 million yuan in the consistency evaluation of the drug. According to market data, the global sales of vitamin B6 injection will be 47.17 million US dollars in 2023, of which the total sales in the Chinese market will be 453 million yuan. In 2024, China Resources Double-Crane achieved revenue of 11.212 billion yuan and net profit attributable to shareholders of the parent company of 1.628 billion yuan. https://finance.eastmoney.com/a/202504223384473457.html
- Source: drugdu
- 166
- April 24, 2025
Weixinkang’s subsidiary potassium magnesium aspartate injection passed the consistency evaluation

April 22, Weixinkang(603676) issued an announcement that recently, the company’s wholly-owned subsidiary Baiyi Pharmaceutical received the “Notice of Approval of Drug Supplementary Application” for potassium magnesium aspartate injection approved and issued by the National Medical Products Administration. The drug successfully passed the generic drug quality and efficacy consistency evaluation. Potassium magnesium aspartate injection is an electrolyte supplement used for the auxiliary treatment of hypokalemia, arrhythmias (mainly ventricular arrhythmias) caused by digitalis poisoning, and sequelae of myocarditis, congestive heart failure, and myocardial infarction. As of the end of March 2025, the company’s cumulative investment in research and development of this drug was RMB 2.0615 million (unaudited). In the first three quarters of 2024, Weixinkang achieved revenue of 994 million yuan and net profit attributable to shareholders of the parent company of 243 million yuan. https://finance.eastmoney.com/a/202504223384343433.html
- Source: drugdu
- 196
- April 24, 2025
Maintaining the leading position of varicella vaccine and deepening the sales track of shingles vaccine and influenza vaccine

On April 21, the company held a performance briefing for 2024 and the first quarter of 2025. Kong Wei, Vice Chairman of the Company, Jiang Chunlai, Director and General Manager, and Zhang Zhe, Secretary of the Board of Directors, interacted and communicated with investors on the specific situation of the operating results and financial indicators for 2024 and the first quarter of 2025. Beike Bio is a high-tech biopharmaceutical company specializing in the research and development, production and sales of human vaccines. The company currently has approved vaccine products such as varicella vaccine, nasal spray influenza vaccine, and shingles vaccine. Among them, the market share of varicella vaccine has been in the leading position for many years; the nasal spray influenza vaccine is a project of the World Health Organization (WHO) Global Influenza Action Plan (GAP), and is the only influenza live attenuated vaccine in China that is administered by ...
- Source: drugdu
- 211
- April 24, 2025
Dentima Krasnodar

Organiser：ITE Group (UK) Time：May 21-23, 2025 address：ul. Zipovskaya, 5, Krasnodar, 350010, Russia Exhibition hall：Krasnodar Expo Center Product range: Medical: Medical supplies, medical products, medical consumables, medical equipment Rehabilitation: Elderly rehabilitation, rehabilitation equipment and materials, rehabilitation medical services, rehabilitation training, rehabilitation devices, aids and equipment for the disabled Health Care: Health supplements, health appliances, health foods, health-related equipment About Dentima Krasnodar： The Russian Medical Exhibition (Dentima Krasnodar) is one of the leading medical exhibitions in the southern region of Russia. Every year, it brings together doctors, manufacturers, and suppliers of medical equipment and materials from many regions of Russia and foreign countries. It serves as a platform for professional exchange and sharing of experiences, showcasing the latest equipment and technologies.
- Source: drugdu
- 150
- April 24, 2025
Just once a week! Ganli Pharmaceutical Co., Ltd. Type 2 diabetes Class 1 new drug approved clinical

On April 21, the official website of the Drug Evaluation Center (CDE) of the State Food and Drug Administration of the People’s Republic of China (CFDA) recently announced that Ganli Pharmaceutical’s Class 1 new drug, GZR102, has obtained the implied license for clinical trials in China and plans to develop and treat type 2 diabetes. According to the announcement of Ganli Pharmaceutical, GZR102 injection is a fixed ratio compound weekly preparation of basic insulin and glucagon like peptide-1 receptor agonist (GLP-1 RA) independently developed by Ganli Pharmaceutical. It is composed of GZR4 injection of under development ultra long acting insulin and GZR18 injection of ultra long acting GLP-1 RA bovaglutide in a fixed ratio. This is the first time that the product has been approved for clinical use in China. Both GZR4 and Bofanglutide have fully explored the drug dosage in the phase II clinical trial carried out in patients ...
- Source: drugdu
- 353
- April 23, 2025
Yunding Xinyao has been approved by the Hong Kong Stock Exchange to remove “B” from its stock code

On April 22, Hong Kong stock innovative pharmaceutical company Yunding Xinyao (01952. HK) announced that the company has obtained approval from the Hong Kong Stock Exchange to remove the “B” mark from its stock code. This marks another milestone in the company’s development history, as Yunding Xinyao has reached higher standards in terms of market value and revenue, and its commercialization capabilities have been further recognized. Since its listing on the Hong Kong Stock Exchange in October 2020, Yunding Xinyao has been focusing on the high-value “blue ocean” field under the “dual wheel drive” strategy of “authorized introduction” and “independent research and development”. At the same time, it is committed to developing innovative therapies that are pioneering or best in class. The company has formed a strong and synergistic platform in the fields of kidney disease, infectious diseases and autoimmune disease, and three commercial products have achieved rapid growth ...
- Source: drugdu
- 299
- April 23, 2025
Maintaining the leading position of varicella vaccine and deepening the sales track of shingles vaccine and influenza vaccine

Baike Bio (688276) held a performance briefing for 2024 and the first quarter of 2025 on April 21. Kong Wei, Vice Chairman of the Company, Jiang Chunlai, Director and General Manager, and Zhang Zhe, Secretary of the Board of Directors, interacted and communicated with investors on the specific situation of the operating results and financial indicators for 2024 and the first quarter of 2025. Baike Bio is a high-tech biopharmaceutical company specializing in the research and development, production and sales of human vaccines. The company currently has approved vaccine products such as varicella vaccine, nasal spray influenza vaccine, and shingles vaccine. Among them, the market share of varicella vaccine has been in the leading position for many years; the nasal spray influenza vaccine is a project of the World Health Organization (WHO) Global Influenza Action Plan (GAP), and is the only influenza live attenuated vaccine in China that is administered ...
- Source: drugdu
- 208
- April 23, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.